Bionano Genomics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bionano Genomics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $4.01M | Mar 14, 2019 |
| FY2018 | Sep 30, 2018 | $2.83M | Mar 14, 2019 |
| FY2018 | Jun 30, 2018 | $3.39M | Mar 14, 2019 |
| FY2018 | Mar 31, 2018 | $1.77M | Mar 14, 2019 |
| FY2018 | Dec 31, 2017 | $2.85M | Mar 14, 2019 |
| FY2018 | Sep 30, 2017 | $2.74M | Mar 14, 2019 |
| FY2018 | Jun 30, 2017 | $2.20M | Mar 14, 2019 |
| FY2018 | Mar 31, 2017 | $1.72M | Mar 14, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.51M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $30.78M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $36.12M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $27.80M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $17.98M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $8.50M | Mar 1, 2022 |
| FY2019 | Dec 31, 2019 | $2.79M | Mar 10, 2020 |
| FY2019 | Sep 30, 2019 | $3.31M | Mar 10, 2020 |
| FY2019 | Jun 30, 2019 | $2.17M | Mar 10, 2020 |
| FY2019 | Mar 31, 2019 | $1.85M | Mar 10, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.40M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($112.02M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($232.49M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($132.60M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($72.44M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($41.11M) | Mar 1, 2022 |
| FY2019 | Dec 31, 2019 | ($7.90M) | Mar 10, 2020 |
| FY2019 | Sep 30, 2019 | ($6.40M) | Mar 10, 2020 |
| FY2019 | Jun 30, 2019 | ($7.66M) | Mar 10, 2020 |
| FY2019 | Mar 31, 2019 | ($7.85M) | Mar 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.34M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($103.98M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($215.25M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($131.70M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($77.10M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($38.55M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($25.87M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($20.42M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($23.22M) | Mar 14, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.37M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $24.80M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $54.03M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $49.05M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $22.49M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $10.26M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $9.08M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $9.48M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $12.01M | Mar 14, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.15M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $51.86M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $92.76M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $88.60M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $58.49M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $31.07M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $20.16M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $14.22M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $14.08M | Mar 14, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.35M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($68.92M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($125.18M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($124.82M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($71.93M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($38.31M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($29.53M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($19.94M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($20.82M) | Mar 14, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | $61.1K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $331.7K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.02M | Mar 14, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.58M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $76.67M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $214.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $307.50M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $377.10M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $60.45M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $30.21M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $24.80M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $10.15M | Mar 14, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.16M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $41.30M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $118.25M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $58.10M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $39.98M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $25.37M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $26.59M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $14.67M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $17.36M | Mar 14, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.42M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $35.38M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $96.16M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $249.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $337.12M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $35.08M | Mar 9, 2023 |
| FY2021 | Dec 31, 2019 | $3.61M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $10.14M | Mar 23, 2021 |
| FY2019 | Dec 31, 2017 | ($50.23M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | ($27.26M) | Mar 14, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $77.29M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $56.16M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $7.17M | Mar 9, 2023 |
| FY2020 | Dec 31, 2019 | $0 | Mar 23, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($719.62M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($693.23M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($581.21M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($348.72M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($216.12M) | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | ($143.68M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($102.58M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($72.76M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($54.27M) | Mar 14, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.99M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $9.17M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $17.95M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $5.09M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $24.57M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | $38.45M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $17.31M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $16.52M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.02M | Mar 14, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $16.33M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $20.08M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $9.03M | Mar 10, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (88) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (408) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (4) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (88) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (408) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (4) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 9, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.74M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 1.87M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 762,533 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 29.72M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 289.60M | Mar 9, 2023 |
| FY2021 | Dec 31, 2020 | 189.95M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 34.27M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 10.06M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 77,257 | Mar 14, 2019 |